An ex vivo gene knockout approach helped the company become first to market with a gene editing therapy

Editas and Tessera report preclinical data for in vivo stem cell editors; Interius doses first patient with an in vivo CAR T

Non-Cas9 enzymes and strategies to improve ex vivo and in vivo engineering of hematopoietic cells are among the innovations

BioCentury’s roundup of translational innovations

Exa-cell from CRISPR and Vertex gets Dec. 8 PDUFA date; Editas pushes competing program forward

Plus Apposite Capital raises third fund and updates from Biogen, Avidity, Vertex-CRISPR and more

Behind Vertex and CRISPR, at least four companies are inhibiting BCL11A for hemoglobinopathies

FDA advisory committee meets this week to discuss lentiviral gene therapies from bluebird

BioCentury’s roundup of translational news

BioCentury’s roundup of translational news